METTL3/YTHDC1-mediated upregulation of LINC00294 promotes hepatocellular carcinoma progression
Heliyon, ISSN: 2405-8440, Vol: 9, Issue: 12, Page: e22595
2023
- 9Citations
- 3Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- CrossRef9
- Captures3
- Readers3
- Mentions1
- News Mentions1
- News1
Most Recent News
New Liver Cancer Research from Shanghai Jiao Tong University School of Medicine Outlined (METTL3/YTHDC1-mediated upregulation of LINC00294 promotes hepatocellular carcinoma progression)
2023 DEC 15 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Investigators publish new report on liver cancer. According to news
Article Description
Hepatocellular carcinoma (HCC) is a highly prevalent malignancy and the third highest contributor to cancer-associated deaths globally. Research has increasingly demonstrated a strong correlation between long noncoding RNAs (lncRNAs) and the incidence and progression of HCC. Nonetheless, the exact mechanism whereby the function of lncRNAs in HCC has not been elucidated. This study explored the pathological role of LINC00294 in HCC, as well as the modulatory mechanism involved. Based on the “The Cancer Genome Atlas (TCGA)” database and validation in HCC cell lines and tissues, the expression of LINC00294 was discovered to be upregulated in HCC tissues and correlated with tumor grade and the prognosis of patients with HCC. Functionally, LINC00294 stimulated the proliferation of HCC cells as well as the Warburg effect (aerobic glycolysis) to enhance progression of tumor in vivo. Mechanistically, METTL3/YTHDC1-mediated N 6 -methyladenosine (m 6 A) modification underwent a significant enrichment within LINC00294 and was shown to enhance its RNA stability. Moreover, LINC00294 promoted the interaction between YTHDC1 and HK2 and GLUT1 mRNA. Overall, our study illustrates the m 6 A modification-mediated epigenetic mechanism of LINC00294 expression and regulatory role in HK2and GLUT1 mRNA expression and indicate LINC00294 as a potential biomarker panel for prognostic prediction and treatment in HCC.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2405844023098031; http://dx.doi.org/10.1016/j.heliyon.2023.e22595; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85178384817&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/38125436; https://linkinghub.elsevier.com/retrieve/pii/S2405844023098031; https://dx.doi.org/10.1016/j.heliyon.2023.e22595
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know